Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
11.13
+0.02 (0.18%)
At close: Aug 13, 2025, 4:00 PM
11.33
+0.20 (1.80%)
Pre-market: Aug 14, 2025, 8:41 AM EDT
Tandem Diabetes Care Stock Forecast
Stock Price Forecast
According to 15 professional analysts, the 12-month price target for Tandem Diabetes Care stock ranges from a low of $10.35 to a high of $51. The average analyst price target of $23.56 forecasts a 111.68% increase in the stock price over the next year.
Price Target: $23.56 (+111.68%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tandem Diabetes Care stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 2 | 2 | 2 |
| Buy | 6 | 6 | 5 | 4 | 4 | 3 |
| Hold | 5 | 6 | 6 | 7 | 6 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 0 |
| Total | 15 | 16 | 15 | 13 | 13 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Sell → Hold Upgrades $10 → $10 | Strong Sell → Hold | Upgrades | $10 → $10 | -7.01% | Aug 12, 2025 |
| Lake Street | Lake Street | Strong Buy → Hold Downgrades $75 → $12 | Strong Buy → Hold | Downgrades | $75 → $12 | +7.82% | Aug 11, 2025 |
| Barclays | Barclays | Buy Maintains $53 → $51 | Buy | Maintains | $53 → $51 | +358.22% | Aug 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $59 → $24 | Strong Buy | Maintains | $59 → $24 | +115.63% | Aug 7, 2025 |
| UBS | UBS | Hold Maintains $20 → $17 | Hold | Maintains | $20 → $17 | +52.74% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
1.02B
from 940.20M
Increased by 8.91%
Revenue Next Year
1.14B
from 1.02B
Increased by 10.94%
EPS This Year
-1.44
from -1.47
EPS Next Year
-0.70
from -1.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1B | 1.3B | 1.4B | ||
| Avg | 1.0B | 1.1B | 1.2B | ||
| Low | 975.4M | 1.0B | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.5% | 24.1% | 23.7% | ||
| Avg | 8.9% | 10.9% | 9.6% | ||
| Low | 3.7% | 1.5% | -2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.17 | -0.26 | 0.96 | ||
| Avg | -1.44 | -0.70 | -0.03 | ||
| Low | -1.65 | -1.38 | -0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.